Avicanna (AVCN) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
30 May, 2026Opening remarks and agenda
Meeting conducted virtually via Lumi platform, enabling live voting for shareholders not voting by proxy.
Chairman, secretary, and scrutineer roles were assigned at the outset.
Notice of meeting and proof of mailing were confirmed and filed.
Quorum was established with at least 51 shareholders representing 36.66% of outstanding shares.
Financial performance review
2024 revenue reached CAD 25.5 million, a 52% increase from 2023.
First profitable quarter in early 2025, with net income of CAD 74,000 and comprehensive income of CAD 876,000.
Gross margins improved to 57% in Q1 2025, up from 46% in Q1 2024.
Adjusted EBITDA loss reduced to CAD 1.4 million in 2024 from CAD 4.3 million in 2023; Q1 2025 saw positive adjusted EBITDA of CAD 430,000.
All debt eliminated in 2024, with accounts payable reduced by CAD 1 million.
Board and executive committee updates
Five directors were nominated and elected to serve until the next annual meeting.
Ramirez Jimenez International CPAs reappointed as auditors for the next year.
Latest events from Avicanna
- 340% revenue growth in 2023 and first EBITDA positive quarter highlight strong momentum.AVCN
AGM 202429 May 2026 - Record Q1 2026 revenue and gross profit achieved amid strong Canadian and proprietary product growth.AVCN
Q1 202614 May 2026 - 2025 saw improved margins, reduced losses, and all AGM proposals passed for future growth.AVCN
AGM 20268 May 2026 - Gross margin rose to 53% in 2025, with near break-even EBITDA and global expansion underway.AVCN
Q4 20257 Apr 2026 - Expanding globally with proprietary cannabinoid medicines and platforms, targeting medical markets.AVCN
Life Sciences Virtual Investor Forum23 Mar 2026 - Poised for scale-up in 2026 with new technologies, clinical progress, and global expansion.AVCN
Status Update17 Dec 2025 - Revenue and unit sales grew, international reach expanded, and new IP was secured in Q3 2025.AVCN
Q3 202526 Nov 2025 - Record revenue, margin gains, and global expansion set the stage for 2025 profitability.AVCN
Q4 202424 Nov 2025 - Gross margin rose to 51% in Q2 2025, with positive six-month adjusted EBITDA and expanded product reach.AVCN
Q2 202525 Aug 2025